[
    [
        {
            "time": "",
            "original_text": "刘格菘第二！年内四只翻倍基金，他竟独占其三",
            "features": {
                "keywords": [
                    "刘格菘",
                    "翻倍基金",
                    "基金经理"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "基金",
                    "投资"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "刘格菘第二！年内四只翻倍基金，他竟独占其三",
                "Correlation": 6,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 4,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "【中金固收·信用】新发降温，二级市场走弱—中资美元债周报",
            "features": {
                "keywords": [
                    "中金固收",
                    "新发降温",
                    "二级市场",
                    "中资美元债"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "债券",
                    "金融市场"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "【中金固收·信用】新发降温，二级市场走弱—中资美元债周报",
                "Correlation": 3,
                "Sentiment": 4,
                "Importance": 5,
                "Impact": 4,
                "Duration": 6,
                "Entity_Density": 2,
                "Market_Scope": 8,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "迈瑞、恒瑞、泰格、石药、华兰生物……上市药企投资价值大PK，你最PICK谁？",
            "features": {
                "keywords": [
                    "迈瑞",
                    "恒瑞",
                    "泰格",
                    "石药",
                    "华兰生物",
                    "投资价值"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "生物科技"
                ],
                "causal_factor": "false",
                "causal_impact": "",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "迈瑞、恒瑞、泰格、石药、华兰生物……上市药企投资价值大PK，你最PICK谁？",
                "Correlation": 8,
                "Sentiment": 6,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 9,
                "Market_Scope": 7,
                "Time_Proximity": 5,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "original_text": "麦格理：升药明康德（02359）目标价9%至152.27元 评级“跑赢大市”",
            "features": {
                "keywords": [
                    "麦格理",
                    "药明康德",
                    "目标价",
                    "跑赢大市"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "麦格理：升药明康德（02359）目标价9%至152.27元 评级“跑赢大市”",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 9,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "明日下午3点！乘风破浪——新型生物技术时代下生物药临床前的生物分析策略 | 生物分析系列(六)",
            "features": {
                "keywords": [
                    "生物技术",
                    "生物药",
                    "临床前",
                    "生物分析"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物科技",
                    "医药"
                ],
                "causal_factor": "false",
                "causal_impact": "",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "明日下午3点！乘风破浪——新型生物技术时代下生物药临床前的生物分析策略 | 生物分析系列(六)",
                "Correlation": 5,
                "Sentiment": 5,
                "Importance": 4,
                "Impact": 3,
                "Duration": 4,
                "Entity_Density": 3,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "original_text": "疫情影响逐渐消退，关注高成长龙头+细分冠军--医药生物上市公司2020年三季报小结",
            "features": {
                "keywords": [
                    "疫情",
                    "高成长龙头",
                    "细分冠军",
                    "三季报"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "疫情影响逐渐消退，关注高成长龙头+细分冠军--医药生物上市公司2020年三季报小结",
                "Correlation": 7,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 6,
                "Market_Scope": 9,
                "Time_Proximity": 5,
                "Headline_Structure": 6,
                "Source_Recency": 5
            }
        },
        {
            "time": "",
            "original_text": "【浙商医药|三季报】创新药研发高景气有望持续，看好CDMO业绩加速",
            "features": {
                "keywords": [
                    "浙商医药",
                    "创新药",
                    "CDMO",
                    "业绩加速",
                    "三季报"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "【浙商医药|三季报】创新药研发高景气有望持续，看好CDMO业绩加速",
                "Correlation": 8,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 7,
                "Market_Scope": 8,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        }
    ]
]